

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)



(10) International Publication Number
WO 2021/202232 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) A61P 37/06 (2006.01)
A61P 35/02 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/024123

(22) International Filing Date:

25 March 2021 (25.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/001,275 28 March 2020 (28.03.2020) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, Texas 78701 (US).

(72) Inventors: **REZVANI, Katy**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030 (US). **SHANLEY, Mayra**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030 (US). **MARIN COSTA, David**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030 (US). **SHAIM, Hila**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030

(US). **SHPALL, Elizabeth**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030 (US).


(74) Agent: **SISTRUNK, Melissa**; Norton Rose Fulbright US LLP, 1301 McKinney Suite 5100, Houston, Texas 77010 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CELL IMMUNOTHERAPY FOR THE TREATMENT OF CANCER

FIG. 1A



(57) Abstract: Embodiments of the disclosure encompass compositions comprising immune effector cells, such as natural killer (NK) cells, where the cells comprise one or more exogenously provided interleukins (IL), and wherein the cell optionally comprises one or more engineered receptors. In specific embodiments, the IL is not IL-15, and is IL-12, IL-21, or both. The NK cells may be utilized for treatment of cancer of any kind, including at least glioblastoma.

[Continued on next page]

WO 2021/202232 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*